Vitamin D: An antiproliferative agent with potential for therapy of squamous cell carcinoma

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 18, Issue 5, 1997, Pages 293-298

  McElwain, Mariann C ^a   Modzelewski, Ruth A ^a   Yu, Wei Dong ^a   Russell, Derick M ^a   Johnson, Candace S ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CELL GROWTH; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; VITAMIN INTAKE;

EID: 0030794319     PISSN: 01960709     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-0709(97)90022-3     Document Type: Review

References (36)

1. Bikle DD, Pillai S: Vitamin D, calcium, and epidermal differentiation. Endocr Rev 14:3-19, 1993
2. Corder EH, Guess HA, Hulka BS, et al: Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-472, 1993
3. Link R, DeLuca HF: The Vitamin D Receptor: The Receptors, vol 2. New York, NY, Academic Press, pp 1-35, 1985
4. Haussler MR, Mangelsdorf DJ, Komm BS, et al: Molecular biology of the vitamin D hormone. Recent Prog Horm Res 44:263-305, 1988
5. 3 receptors as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 53:3712-3718, 1993
6. 3 receptors in human carcinomas: A pilot study. Cancer Res 51:2021-2024, 1991
7. 3 induced differentiation in a human promyelocytic leukemia cell line HL-60: Receptor-mediated maturation to macrophage-like cells. J Cell Biol 98:391-398, 1984
8. 3 receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology 118:1119-1126, 1986
9. 3 receptors: Divergent effects on mouse and rat intestine. Endocrinology 111:1400-1402, 1982
10. 3 inhibits the clonogenic growth of transformed cells via its receptor. Biochem Biophys Res Commun 139:136-143, 1986
11. 3. Proc Natl Acad Sci USA 78:4990-4994, 1981
12. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87:3929-3932, 1990
13. Olsson I, Gullbert U, Ivhed I, et al: Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1α,25-dihydroxycholecalciferol. Cancer Res 32:5862-5867, 1983
14. 3 receptors in human leukocytes. Science 221:1181-1183, 1983
15. Garland CF, Garland FC: Do sunlight and vitamin D reduce the risk of colon cancer? Int J Epidemiol 9:227-231, 1980
16. Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis) Anticancer Res 10:1307-1312, 1990
17. Colston KW, Berger U, Coombes RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 28:188-191, 1989
18. Colston KW, Chander SK, Mackay AG, et al: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693-702, 1993
19. 3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms. Cancer Res 54:1458-1464, 1994
20. 3 on the morphology of human breast cancer cell line BT.20. Differentiation 40:63-69, 1989
21. Garland CF, Garland FC, Shaw EK, et al: Serum 25-hydroxyvitamin D and colon cancer. Eight-year prospective study. Lancet 2:1176-1178, 1989
22. 3. Cancer Res 47:21-25, 1987
23. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810, 1994
24. 3. Cancer Res 52:515-520, 1993
25. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1959, 1993
26. Davies M: High-dose vitamin D therapy: Indications, benefits and hazards, in Walter P, Brubaker G, Stahelin H (eds): Elevated Dosages of Vitamins. Lewiston, NY, Hans Huber, 1989, pp 81-86
27. Cunningham D, Gilchrist NL, Cowan RA, et al: Alfacalcidol as a modulatory of growth of low grade non-Hodgkin's lymphomas. Br Med J 291:1153-1155, 1985
28. 3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69:1399-1407, 1985
29. Selgas R, Martinez ME, Miranda B, et al: The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 13:122-125, 1993
30. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87:3929-3932, 1990
31. Zhou J-Y, Norman AW, Lubbert M, et al: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 74:82-93, 1989
32. 3. Differential effects on leukemia cell growth, differentiation and intestinal calcium absorption. Cancer Res 50:6857-6864, 1990
33. 3 analogue in a squamous cell carcinoma model system. Mol Cell Diff 3:31-50, 1995
34. Johnson CS, Chang M-J, Yu W-D, et al: Synergistic enhancement by inter-leukin-1α of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemother Pharmacol 32:339-346, 1993
35. Heo DS, Snyderman CH, Gollin SM, et al: Biology, cytogenetics and sensitivity to immunologic effector cells of new head and neck squamous cell carcinoma. Cancer Res 49:5167-5175, 1989
36. McElwain MC, Russell DM, Modzelewski RA, et al: Enhanced anti-tumor activity of 1,25-dihydroxycholecalciferol by dexamethasone in squamous cell carcinoma. Proc Am Assoc Cancer Res 36:273, 1995 (abstr)